Medicine
Audio Journal of Medicine
In this edition:
1. Training In Depression And Suicide: Need For Change?
Stan Kutcher, Dalhousie University, Nova Scotia
2. Suicide Paradox Explained: Australian National Strategy
Barry Nurcombe, Princess Margaret Hospital, Perth
3. Methylphenidate in the Real World
Manfred Döpfner, University of Cologne
4. Long Acting ADHD Treatments: Not All The Same
David Coghill, University of Dundee
Ralph Littlejohn interviewed some of the key speakers at the 2008 international conference on child mental health.
Debate: Adjuvant Chemotherapy Should Be Standard in Stage I Non-Small Cell Lung Cancer
Giorgio Scagliotti
Robert Pirker
GIORGIO SCAGLIOTTI, University of Turin
ROBERT PIRKER, Medical University of Vienna
A heated debate took place at the European Congress on Lung Cancer in Turin between Robert Pirker who is in favor of offering adjuvant chemotherapy to selected patients who have stage I non-small cell lung cancer, and Giorgio Scagliotti who took the opposite point of view. Peter Goodwin got them together and asked them to talk about the key issues influencing their views.
ROBERT PIRKER, Medical University of Vienna
A heated debate took place at the European Congress on Lung Cancer in Turin between Robert Pirker who is in favor of offering adjuvant chemotherapy to selected patients who have stage I non-small cell lung cancer, and Giorgio Scagliotti who took the opposite point of view. Peter Goodwin got them together and asked them to talk about the key issues influencing their views.
New Targets Bring Promise For Lung Cancer Therapy
Egbert Smit
EGBERT SMIT, Free University of Amsterdam
There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He talked with Peter Goodwin about insulin-like growth factor inhibitors, heat shock protein and an inhibitor of angiogenesis involving the c-MET protein.
There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He talked with Peter Goodwin about insulin-like growth factor inhibitors, heat shock protein and an inhibitor of angiogenesis involving the c-MET protein.
Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors
Silvia Novello
SILVIA NOVELLO, University of Turin
Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello when she presented data on a range of drugs which target angiogenesis by inhibiting more than one tyrosine kinase pathway. She talked about the evidence so far with Peter Goodwin.
Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello when she presented data on a range of drugs which target angiogenesis by inhibiting more than one tyrosine kinase pathway. She talked about the evidence so far with Peter Goodwin.
Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?
Timothy Illidge
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
TIMOTHY ILLIDGE, Christie Hospital, Manchester
Radioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according to Tim Illidge who told the Paris conference that tositumomab and ibritumomab tiuxetan have already proved effective. He explained to Peter Goodwin why he thinks the latest data look promising.
TIMOTHY ILLIDGE, Christie Hospital, Manchester
Radioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according to Tim Illidge who told the Paris conference that tositumomab and ibritumomab tiuxetan have already proved effective. He explained to Peter Goodwin why he thinks the latest data look promising.
Meta-Analysis Proves Statins Help Patients With Diabetes
Colin Baigent
REFERENCE: Lancet 371:117 January 11, 2008
COLIN BAIGENT, Oxford University
Statins were found to cut cardiovascular event rates by a fifth among patients with both Type I and Type II diabetes in a meta-analysis of 18 000 patients from Oxford University in England and the University of Sydney in Australia. Peter Goodwin asked the lead UK investigator, Colin Baigent, about the findings and their implications.
COLIN BAIGENT, Oxford University
Statins were found to cut cardiovascular event rates by a fifth among patients with both Type I and Type II diabetes in a meta-analysis of 18 000 patients from Oxford University in England and the University of Sydney in Australia. Peter Goodwin asked the lead UK investigator, Colin Baigent, about the findings and their implications.
Non Drug Intervention: Better Than Antipsychotic Drugs for Aggressive Challenging Behaviour in Intellectual Disability
Peter Tyrer
REFERENCE: Lancet 371:57 January 5, 2008
PETER TYRER, Imperial College, W6 8RP London
A randomized study comparing treatment with risperidone, or haloperidol, or placebo to treat patients who have intellectual disability presenting with a syndrome commonly labelled as “aggressive challenging behaviour” has shown that the anti-psychotic medicines gave no benefit. Peter Goodwin met up with Professor Peter Tyrer at London’s Imperial College to ask him about the study.
PETER TYRER, Imperial College, W6 8RP London
A randomized study comparing treatment with risperidone, or haloperidol, or placebo to treat patients who have intellectual disability presenting with a syndrome commonly labelled as “aggressive challenging behaviour” has shown that the anti-psychotic medicines gave no benefit. Peter Goodwin met up with Professor Peter Tyrer at London’s Imperial College to ask him about the study.
New Drug AMG 531 Effective in Splenectomized Patients with Chronic Immune Thrombocytopenic Purpura
Terry Gernsheimer
TERRY GERNSHEIMER, University of Washington Medical Center, Seattle
An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial that randomized patients to receive either the novel agent or a placebo. Sarah Maxwell spoke to study author Terry Gernsheimer from the University of Washington during the American Society of Hematology meeting in Atlanta.
An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chronic immune thrombocytopenic purpura or ITP. This was in a placebo controlled phase III trial that randomized patients to receive either the novel agent or a placebo. Sarah Maxwell spoke to study author Terry Gernsheimer from the University of Washington during the American Society of Hematology meeting in Atlanta.
Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
Bengt Eriksson
REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when compared to enoxaparin. Derek Thorne heard more from Bengt Eriksson of Gothenburg University.
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when compared to enoxaparin. Derek Thorne heard more from Bengt Eriksson of Gothenburg University.
Colistin Use Linked to Outbreak of Rare Hospital Infection
Ramon Guevara
REFERENCE: Abstract K-1942, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
RAMON GUEVARA, Los Angeles County Department of Public Health
A report on a hospital outbreak involving a rare pathogen, which was presented at ICAAC, may have an important message for the whole field of infection control. Elizabethkingia Meningoseptica was found in a Los Angles hospital outbreak in 2006 and its emergence was linked to the use of colistin. So was this antibiotic selecting for the pathogen? Derek Thorne spoke with Ramon Guevara of Los Angeles County Department of Public Health.
RAMON GUEVARA, Los Angeles County Department of Public Health
A report on a hospital outbreak involving a rare pathogen, which was presented at ICAAC, may have an important message for the whole field of infection control. Elizabethkingia Meningoseptica was found in a Los Angles hospital outbreak in 2006 and its emergence was linked to the use of colistin. So was this antibiotic selecting for the pathogen? Derek Thorne spoke with Ramon Guevara of Los Angeles County Department of Public Health.
Which HIV Treatment is Best for Patients with HIV and Hepatitis C?
Juan Berenguer
REFERENCE: Abstract V-1385, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JUAN BERENGUER, Hospital Gregorio Marañón, Madrid
A retrospective study has thrown doubt on the theory that protease inhibitors (PIs) are a preferable antiretroviral treatment for patients co-infected with HIV and Hepatitis C virus. Previous research had suggested that PIs had a more beneficial effect on liver fibrosis than NNRTIs, but a study based at the Hospital Gregorio Marañón in Madrid has found the opposite. Derek Thorne discussed the data with Juan Berenguer.
JUAN BERENGUER, Hospital Gregorio Marañón, Madrid
A retrospective study has thrown doubt on the theory that protease inhibitors (PIs) are a preferable antiretroviral treatment for patients co-infected with HIV and Hepatitis C virus. Previous research had suggested that PIs had a more beneficial effect on liver fibrosis than NNRTIs, but a study based at the Hospital Gregorio Marañón in Madrid has found the opposite. Derek Thorne discussed the data with Juan Berenguer.
Broad Approach, Including Computer System, to Improve Hospital Hygiene
Yehuda Carmeli
REFERENCE: Abstract K-1373, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
YEHUDA CARMELI, Tel-Aviv Medical Center
Hospitals can prevent significant numbers of infections by taking up a multi-faceted approach, including the use of a computer program to guide the isolation of patients. Derek Thorne spoke to Yehuda Carmeli of the Tel-Aviv Medical Center about his hospital’s experience.
YEHUDA CARMELI, Tel-Aviv Medical Center
Hospitals can prevent significant numbers of infections by taking up a multi-faceted approach, including the use of a computer program to guide the isolation of patients. Derek Thorne spoke to Yehuda Carmeli of the Tel-Aviv Medical Center about his hospital’s experience.
Bivalirudin For Angioplasty: Expensive Heparin?»
Tony Gershlick, University of Leicester
Adnan Kastrati, Deutsches Herzzentrum, Munich
Using bivalirudin instead of heparin during angioplasty wasn't any better for preventing death, MI or urgent revascularisation in the 4,500-patient ISAR-REACT 3 study presented at the ACC annual meeting. Tony Gershlick and Adnan Kastrati discuss the study with Peter Goodwin and Sarah Freeman.Tony Gershlick, University of Leicester
Adnan Kastrati, Deutsches Herzzentrum, Munich
Tropical Health Research: London Scientist Honored»
Brian Greenwood, London School of Hygiene and Tropical Medicine
Brian Greenwood, of the London School of Hygiene and Tropical Medicine, has won the Hideyo Noguchi Africa Prize for his numerous achievements in tropical disease research. He talked withy Derek Thorne about his work, including the pivotal research proving that bed nets can help prevent malaria.Brian Greenwood, London School of Hygiene and Tropical Medicine
© 2008 Audio Medica - Medical Audio News Interviews & Podcasts. 
